CTKB Stock Overview
A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CTKB from our risk checks.
Cytek Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.57 |
| 52 Week High | US$9.87 |
| 52 Week Low | US$3.80 |
| Beta | 1.33 |
| 11 Month Change | 2.77% |
| 3 Month Change | -14.83% |
| 1 Year Change | -32.81% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.31% |
Recent News & Updates
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Recent updates
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Checking In On Cytek Biosciences
Mar 23Shareholder Returns
| CTKB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.5% | -3.0% | 1.0% |
| 1Y | -32.8% | -2.9% | 23.6% |
Return vs Industry: CTKB underperformed the US Life Sciences industry which returned -2.9% over the past year.
Return vs Market: CTKB underperformed the US Market which returned 23.6% over the past year.
Price Volatility
| CTKB volatility | |
|---|---|
| CTKB Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CTKB has not had significant price volatility in the past 3 months.
Volatility Over Time: CTKB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 637 | Wenbin Jiang | cytekbio.com |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.
Cytek Biosciences, Inc. Fundamentals Summary
| CTKB fundamental statistics | |
|---|---|
| Market cap | US$731.19m |
| Earnings (TTM) | -US$11.51m |
| Revenue (TTM) | US$200.79m |
3.6x
P/S Ratio-63.5x
P/E RatioIs CTKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTKB income statement (TTM) | |
|---|---|
| Revenue | US$200.79m |
| Cost of Revenue | US$89.39m |
| Gross Profit | US$111.40m |
| Other Expenses | US$122.91m |
| Earnings | -US$11.51m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | 55.48% |
| Net Profit Margin | -5.73% |
| Debt/Equity Ratio | 0.9% |
How did CTKB perform over the long term?
See historical performance and comparison